Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18262546 | 1.00 | LDHA (0.36) | LDHACTBP2KMT2AMMP1MMP3 | |
| SCHEMBL18262544 | 1.00 | LDHA (0.36) | LDHACTBP2KMT2AMMP1MMP3 | |
| SCHEMBL28562309 | 0.90 | ITGB3 (0.44) | MMP1ALDH1A1CTSLITGB3ITGA2B | |
| SCHEMBL18262421 | 0.89 | LDHA (0.39) | LDHAKMT2AMMP1MMP3MMP9 | |
| SCHEMBL18262422 | 0.89 | LDHA (0.39) | LDHAKMT2AMMP1MMP3MMP9 | |
| SCHEMBL28562308 | 0.82 | SCN9A (0.35) | LDHACTBP2KDM4EALDH1A1ACACB | |
| SCHEMBL28564659 | 0.81 | LDHA (0.34) | LDHACTBP2KDM4EALDH1A1ACACB | |
| SCHEMBL28564662 | 0.81 | LDHA (0.34) | LDHACTBP2KDM4EALDH1A1ACACB | |
| SCHEMBL28558406 | 0.79 | ITGB3 (0.46) | ALDH1A1CTSLITGB3ITGA2B | |
| SCHEMBL20415684 | 0.79 | ITGB3 (0.46) | ALDH1A1CTSLITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3303284-B1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3303284-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016189877-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | LDHA 4466/4885CTBP2 4021/4885KMT2A 4461/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | LDHA 4452/4885CTBP2 4056/4885KMT2A 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.